510(k) Report

510(k) · Cleared

Cleared

Civastring PD-103

K082159510(k) TraditionalCleared Sep 30, 200861-day reviewClass II21 CFR 892.5730

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Civatech Oncology, Inc. · KXK Source, Brachytherapy, Radionuclide

Cleared on Sep 30, 2008 as substantially equivalent to K001070 (Radiomed Corp., 2000) and 2 other predicates after a 61-day review. Its family tree reaches back 2 generations to 1987. 1 later device descends from it.

Decided
Sep 30, 2008
Review
61 days
Class
Class II
Product code
KXK
Recalls
None
Predicates
3

Its longest line of descent runs back 2 generations to K874787 (1987). 5 ancestors in all. 1 later device descends from it, 1 citing it directly.

Other ancestors, by year clearedDescendants, by year cleared 2004: 1 other ancestor2003: 1 other ancestor1994: 1 other ancestor2014: 1 descendant clearedK874787 · Modified Palladium Seed Model 100 · Theragenics Corp. · 1987K001070 · Radiomed Source · Radiomed Corp. · 20001990200020102020
Other ancestors, by generationDescendants, by generation 1 generation back: 2 other ancestors2 generations back: 1 other ancestor 1 generation forward: 1 descendant K001070 · Radiomed Source · Radiomed Corp. · 2000K874787 · Modified Palladium Seed Model 100 · Theragenics Corp. · 19870
  1. Root · 2 generations backK874787 Modified Palladium Seed Model 100Theragenics Corp. · 1987
  2. 1 generation backK001070 Radiomed SourceRadiomed Corp. · 2000
  3. This deviceK082159 Civastring PD-103Civatech Oncology, Inc. · 2008
  4. Descendant · cites it directly · 0 of its ownK140490 Civa Sheet PD-103Civatech Oncology, Inc. · 2014

Most influential descendants

Showing 1 of 1 · See all
  • K140490Civa Sheet PD-103Civatech Oncology, Inc. · 2014 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K874787Modified Palladium Seed Model 100Theragenics Corp.1987—
−1K001070Radiomed SourceRadiomed Corp.2000—
0 (this device)K082159Civastring PD-103Civatech Oncology, Inc.2008—
+1K140490Civa Sheet PD-103Civatech Oncology, Inc.2014—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199410
200310
200410

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201410
FIG. 1 — Lineage of K082159, 1987–2014Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KXK? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new KXK device

  1. #1 K242818 IsoSpherescore 10.9 · 5 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (3)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K001070Radiomed SourceRadiomed Corp.2000—
*K040766Optisource, Model 1032P
Summary page 1
…ing predicate devices: · RadioMedTM Source by RadioMed Corporation, 510(k) KO01070 * OptiSource 1 3 °by International Brachytherapy, Inc., 5 10(k) K040766 · Readi-Strand Model PSStrand by Worldwide Medical Technologies, Inc., 510(k) K023179 4. Device De…
International Brachytherapy S.A.2004—
*K023179Readi-Strand, Model Psstrand
Summary page 1
…tiSource 1 3 °by International Brachytherapy, Inc., 5 10(k) K040766 · Readi-Strand Model PSStrand by Worldwide Medical Technologies, Inc., 510(k) K023179 4. Device Description: CivaStringPd 1° 3 is a linear LDR (low dose rate) brachytherapy source comprised of…
Worldwide Medical Technologies, LLC2003—

Also cleared against K001070: 1 other device →

What descends from it? (1)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K140490Civa Sheet PD-103Civatech Oncology, Inc.20140

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 21 years and passes through 3 companies; a new generation was cleared every 12.8 years on median.
  • None of the 5 ancestors has a recall.
  • Of its descendants, K140490 (Civatech Oncology, Inc., 2014) has gone furthest, with 0 descendants of its own.
  • 1 other device also cites its predicate K001070.

How does its category compare?

All KXK devices

KXK Source, Brachytherapy, Radionuclide: FDA decisions, review times, recalls and adverse event reports over 20 years. 2008, this device’s year, is highlighted.

FDA decisions per year · KXK

2in 2025

2007: 52008: 12009: 72010: 12011: 52012: 32013: 32014: 82015: 22016: 42017: 22018: 12019: 22020: 32022: 12023: 12025: 2
2007high 8 (2014) · low 0 (2021)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KXK

158in 2020

2007: 42 days median2009: 63 days median2011: 94 days median2012: 109 days median2013: 127 days median2014: 96 days median2016: 49 days median2020: 158 days median
2007high 158 (2020) · low 42 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · KXK

1in 2016

2008: 12011: 12012: 12016: 1
2007high 1 (2008) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · KXK

7in 2025

2007: 92008: 152009: 102011: 352012: 42013: 292014: 132015: 62016: 402017: 412018: 282019: 102020: 152021: 622022: 262023: 92024: 152025: 7
2007high 62 (2021) · low 0 (2010)2025

MAUDE reports naming product code KXK, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
200754209
20081—115
2009763010
20101—00
2011594135
2012310914
20133127029
2014896013
20152—06
2016449140
20172—041
20181—028
20192—010
20203158015
20210—062
20221—026
20231—09
20240—015
20252—07
20260—0—

What is it indicated for?

CivaStringPdl° 3 is indicated for use as a permanent interstitial brachytherapy source for the treatment of selected localized tumors. The device may be used either as the primary treatment or for treatment of residual disease after excision of the primary tumor. CivaStringPdl° 3 may be indicated for use concurrently with or sequentially with other treatment modalities, such as external beam radiation therapy or chemotherapy.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K082159: Civastring PD-103.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K082159

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026